<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02186561</url>
  </required_header>
  <id_info>
    <org_study_id>NV-PED-07</org_study_id>
    <nct_id>NCT02186561</nct_id>
    <nct_alias>NCT02178007</nct_alias>
  </id_info>
  <brief_title>Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device</brief_title>
  <acronym>PREMIER</acronym>
  <official_title>PREMIER PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE™ EMBOLIZATION DEVICE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the Pipeline™ device
      in the treatment of unruptured, wide-neck intracranial aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of major stroke or neurological death</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete aneurysm occlusion</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major stroke or neurological death</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Device-related neurologic adverse event</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aneurysm occlusion</measure>
    <time_frame>3 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Pipeline™ Embolization Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with Pipeline™ Embolization Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device</intervention_name>
    <arm_group_label>Pipeline™ Embolization Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided written informed consent using the IRB/EC-approved consent form
             and agrees to comply with protocol requirements.

          -  Age 22-80 years.

          -  Subject has a target intracranial aneurysm (IA) located in the anterior or posterior
             circulation.

          -  Subject has a target IA with a wide aneurysm neck.

        Exclusion Criteria:

          -  Subject has received an intracranial implant (e.g. coils) in the area of the target
             IA within the past 12 weeks.

          -  Major surgery in the last 30 days.

          -  History of irreversible bleeding disorder and/or subject presents with signs of
             active bleeding.

          -  Any known contraindication to treatment with the Pipeline™ device.

          -  Pregnant women.

          -  Participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baptist Medical Center Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 25, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracranial aneurysm</keyword>
  <keyword>brain aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
